about
Roles of the Picornaviral 3C Proteinase in the Viral Life Cycle and Host CellsReplication and Inhibitors of Enteroviruses and ParechovirusesBroad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses.Therapeutic and prevention strategies against human enterovirus 71 infectionAntiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolatesThe capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.Dominant drug targets suppress the emergence of antiviral resistancePhosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.Synthesis of novel purine-based coxsackievirus inhibitors bearing polycylic substituents at the N-9 position.Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71.Future of polio vaccines.The need for treatment against human parechoviruses: how, why and when?Highlights in antiviral drug research: antivirals at the horizon.Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.Enterovirus D-68: an emerging cause of infection.The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.Structure-based antivirals for emerging and neglected RNA viruses: an emerging field for medicinal chemistry in academia.In Vitro Efficacy of Antiviral Compounds against Enterovirus D68.Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio EradicationMutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.Antipoliovirus Activity of the Organic Extract of Eupatorium buniifolium: Isolation of Euparin as an Active Compound.Emerging antiviral drugsAntivirals: current state of the art
P2860
Q26753001-997CC1D7-4879-42E4-A452-E8C941C33B4BQ26798463-ACB21ED7-F47B-4236-A3EC-35D955C2C803Q27671667-B39C3FA3-0689-4A59-9C51-AA422933238DQ28080796-69F271E6-A053-4693-B70F-CF3860DD7DABQ28478276-2C529446-5B61-47E2-B378-B7DD7CD5E9C7Q34596364-308511AF-2B83-4C52-ADD6-E4455FC8C72FQ34729490-7A06912A-C1AB-4952-9E34-873C8B156C6CQ34742005-4F06CACA-46DE-4F35-9739-18FCE5889869Q35126871-4C163F0E-A0F2-473B-8756-A73D8BFCA424Q36760237-C83F9C35-2F4E-42CB-A784-B15FBF59A863Q37247709-FE45D8DB-F5CE-4DAD-A5C2-183C3CD0D42AQ37450453-074CC36C-7E83-4AEA-9239-1BF44F415AAEQ37816394-01E0C12D-8D27-4CF8-A0F0-7959C02E741AQ38007145-55B37556-CEA1-4454-AC6E-4239AED8BACFQ38028997-69D30D8F-4463-437B-8B30-B9D44322AD53Q38323836-93986BE1-1043-4E37-B4F0-C297307CE2E5Q38946420-70E379EA-CFD6-447C-B37E-9E35F0106B71Q38988957-9D3DE2B7-EF33-4AE7-8F9D-D806273F3575Q39067597-F17B9FE1-E16C-43A0-A29A-214D413A8C37Q41120057-3A84905C-82AF-4F50-86B6-4560B2CB99E0Q41779600-87C09024-9E56-4FBF-8A8E-906B96B3AD3BQ41827009-1B3DB5FF-78C1-4C51-AD90-A36A12515F7FQ42275815-5619F512-E46A-47B4-9A02-B2412BACC99AQ56786308-C065989A-5E8D-42EE-941B-D09B095A7652Q56786312-5F13E915-144D-42DD-8C6A-7FD48BFECD6F
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Potential use of antiviral agents in polio eradication.
@en
type
label
Potential use of antiviral agents in polio eradication.
@en
prefLabel
Potential use of antiviral agents in polio eradication.
@en
P2093
P2860
P356
P1476
Potential use of antiviral agents in polio eradication.
@en
P2093
Amy K Patick
Armando M De Palma
Bart Rombaut
Eva Wimmer
Gerhard Pürstinger
Koen Andries
P2860
P304
P356
10.3201/EID1404.070439
P577
2008-04-01T00:00:00Z